

CITATION REPORT

List of articles citing

Long-term sildenafil added to intravenous
epoprostenol in patients with pulmonary arterial hypertension

DOI: 10.1016/j.healun.2014.02.019

Journal of Heart and Lung Transplantation, 2014, 33, 689-97.

Source: <https://exaly.com/paper-pdf/58697279/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Epoprostenol (Veletri [®] , Caripul [®]): a review of its use in patients with pulmonary arterial hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2014 , 14, 463-70	4	9
20	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <i>Global Cardiology Science & Practice</i> , 2014 , 2014, 257-90	0.7	10
19	Diagnosis and Management of Pulmonary Hypertension. <i>Respiratory Medicine</i> , 2015 ,	0.2	
18	A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy. <i>Journal of Clinical Medicine</i> , 2016 , 5,	5.1	12
17	[Targeted therapy of pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016]. <i>Deutsche Medizinische Wochenschrift</i> , 2016 , 141, S33-S41	0	12
16	[Rehabilitation standards for follow-up treatment and rehabilitation of patients with ventricular assist device (VAD)]. <i>Clinical Research in Cardiology Supplements</i> , 2016 , 11 Suppl 1, 2-49	3.1	13
15	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. <i>Drug Safety</i> , 2016 , 39, 287-94	5.1	26
14	A review of therapeutic agents for the management of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2017 , 11, 46-63	4.9	8
13	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018 , 272S, 37-45	3.2	33
12	Combination Therapy in Pulmonary Arterial Hypertension: Gleaning a Practical Approach from the Randomized Trials. <i>International Journal of Angiology</i> , 2019 , 28, 93-99	1.1	
11	Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2019 , 25,	0.2	
10	Six-Minute Walk Test: Clinical Role, Technique, Coding, and Reimbursement. <i>Chest</i> , 2020 , 157, 603-611	5.3	45
9	Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment. <i>Comprehensive Physiology</i> , 2021 , 11, 2135-2190	7.7	2
8	Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis. <i>Drug Delivery</i> , 2021 , 28, 1007-1019	7	2
7	Combination Therapy for the Treatment of Pulmonary Arterial Hypertension. <i>Respiratory Medicine</i> , 2015 , 377-396	0.2	
6	Perioperative Nursing for Adult Congenital Heart Disease with Severe Pulmonary Arterial Hypertension. <i>International Journal of Clinical Medicine</i> , 2020 , 11, 538-547	0.3	
5	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. <i>Advances in Therapy</i> , 2021 , 39, 796	4.1	4

4	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway. <i>Frontiers in Pharmacology</i> , 2021 , 12, 767002	5.6	4
3	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. <i>Advances in Therapy</i> ,	4.1	
2	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
1	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58